Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925001119 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849727896207228928 |
|---|---|
| author | Reid Shaw James J. Yoon Hannah Johnston Marta B. Davidson Alexa J. Siddon Rory M. Shallis Evan C. Chen Madelyn Burkart Timothy S. Oh Sunil G. Iyer Ellen Madarang Chandrasekar Muthiah Joshua Kassner Raajit K. Rampal Guru Subramanian Guru Murthy Terrence Bradley Yasmin Abaza Jacqueline S. Garcia Vikas Gupta Kristen M. Pettit Olatoyosi Odenike Anand A. Patel |
| author_facet | Reid Shaw James J. Yoon Hannah Johnston Marta B. Davidson Alexa J. Siddon Rory M. Shallis Evan C. Chen Madelyn Burkart Timothy S. Oh Sunil G. Iyer Ellen Madarang Chandrasekar Muthiah Joshua Kassner Raajit K. Rampal Guru Subramanian Guru Murthy Terrence Bradley Yasmin Abaza Jacqueline S. Garcia Vikas Gupta Kristen M. Pettit Olatoyosi Odenike Anand A. Patel |
| author_sort | Reid Shaw |
| collection | DOAJ |
| format | Article |
| id | doaj-art-2ccee6d3e3214b7fa507f84ee429770f |
| institution | DOAJ |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-2ccee6d3e3214b7fa507f84ee429770f2025-08-20T03:09:43ZengElsevierBlood Advances2473-95292025-05-019102453245710.1182/bloodadvances.2024015712Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapyReid Shaw0James J. Yoon1Hannah Johnston2Marta B. Davidson3Alexa J. Siddon4Rory M. Shallis5Evan C. Chen6Madelyn Burkart7Timothy S. Oh8Sunil G. Iyer9Ellen Madarang10Chandrasekar Muthiah11Joshua Kassner12Raajit K. Rampal13Guru Subramanian Guru Murthy14Terrence Bradley15Yasmin Abaza16Jacqueline S. Garcia17Vikas Gupta18Kristen M. Pettit19Olatoyosi Odenike20Anand A. Patel21Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, ILLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, ILDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, CanadaDepartments of Laboratory Medicine and Pathology, Yale School of Medicine, New Haven, CTHematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CTDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MAAtrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NCDivision of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, ILDivision of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NYDepartment of Pharmacy, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FLDepartment of Internal Medicine, Medical College of Wisconsin, Milwaukee, WIDivision of Hematology and Medical Oncology, Weill Department of Medicine, Cornell University, Ithaca, NYLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYDivision of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WIDepartment of Pharmacy, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FLDivision of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, ILDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MADivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, CanadaDivision of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan Medical School, Michigan Medicine, Ann Arbor, MISection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, ILSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Correspondence: Anand A. Patel, Section of Hematology/Oncology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637;http://www.sciencedirect.com/science/article/pii/S2473952925001119 |
| spellingShingle | Reid Shaw James J. Yoon Hannah Johnston Marta B. Davidson Alexa J. Siddon Rory M. Shallis Evan C. Chen Madelyn Burkart Timothy S. Oh Sunil G. Iyer Ellen Madarang Chandrasekar Muthiah Joshua Kassner Raajit K. Rampal Guru Subramanian Guru Murthy Terrence Bradley Yasmin Abaza Jacqueline S. Garcia Vikas Gupta Kristen M. Pettit Olatoyosi Odenike Anand A. Patel Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy Blood Advances |
| title | Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy |
| title_full | Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy |
| title_fullStr | Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy |
| title_full_unstemmed | Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy |
| title_short | Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy |
| title_sort | assessing aml based risk criteria in patients with accelerated blast phase mpn treated with less intensive therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2473952925001119 |
| work_keys_str_mv | AT reidshaw assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT jamesjyoon assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT hannahjohnston assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT martabdavidson assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT alexajsiddon assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT rorymshallis assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT evancchen assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT madelynburkart assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT timothysoh assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT sunilgiyer assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT ellenmadarang assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT chandrasekarmuthiah assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT joshuakassner assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT raajitkrampal assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT gurusubramaniangurumurthy assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT terrencebradley assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT yasminabaza assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT jacquelinesgarcia assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT vikasgupta assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT kristenmpettit assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT olatoyosiodenike assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy AT anandapatel assessingamlbasedriskcriteriainpatientswithacceleratedblastphasempntreatedwithlessintensivetherapy |